Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Public ClinicalTrials.gov record NCT00363051. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label, Stratified, Single-arm Phase II Study of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumor (NET) After Failure of Cytotoxic Chemotherapy
Study identification
- NCT ID
- NCT00363051
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Interventions
- Everolimus 10 mg Drug
- Octreotide Depot Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Dec 31, 2007
- Completion
- Mar 31, 2012
- Last update posted
- May 9, 2013
2006 – 2012
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| USC Medical Center | Los Angeles | California | 90033 | — |
| Cedars-Sinai Outpatient Cancer Center/Samuel Oschin Comprehensive Cancer Inst. | Los Angeles | California | 90048 | — |
| UCLA Medical Center | Los Angeles | California | 90073 | — |
| UCSF Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| University of Miami | Miami | Florida | 33136 | — |
| H. Lee Moffit Cancer Center & Research Institute | Tampa | Florida | 33612 | — |
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| LSUHC Multispecialty Clinic | New Orleans | Louisiana | 70115 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Lynn Ratner, M.D. | New York | New York | 10028 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Arthur G. James Cancer Hospital/Ohio State University | Columbus | Ohio | 43210 | — |
| Oregon Health and Science University | Portland | Oregon | 97239-3098 | — |
| M. D Anderson Cancer Center | Houston | Texas | 77030 | — |
| Scott & White Memorial Hospital | Temple | Texas | 76508 | — |
| University of Wisconsin Hospital & Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00363051, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 9, 2013 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00363051 live on ClinicalTrials.gov.